Funding for this research was provided by:
Center for Thoracic Oncology Icahn School of Medicine at Mount Sinai
Borsa Dottorati XXXII FSE Ciclo Unime
NIH NCI (P30CA016672)
National Cancer Institute (P30CA047904)
Associazione Siciliana Sostegno Oncologico Onlus.
National Cancer Institute - Cancer Center Support (P30CA134274)
Merck Sharp and Dohme
Received: 20 March 2022
Accepted: 2 May 2022
First Online: 2 June 2022
: All patients consented to sample and data collection and Institutional Review Boards approved the study protocol. No patient personal data is being published.
: All the authors agree to the content of the paper and are being listed as a co-author of the paper.
: A. Russo reports advisory board role/consultancy for AstraZeneca, Novartis, and MSD outside the submitted work. A. F. Cardona disclose financial research support from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Foundation Medicine, Roche Diagnostics, Thermo Fisher, Broad Institute, BioNTech, Amgen, Flatiron Health, Teva Pharma, Rochem Biocare, Bayer, INQBox and The Foundation for Clinical and Applied Cancer Research – FICMAC. Additionally, he was linked and received honoraria as an advisor, participated in speakers' bureau and gave expert testimony to EISAI, Merck Serono, Jannsen Pharmaceutical, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant Health, Illumina, and Foundation for Clinical and Applied Cancer Research – FICMAC. A. Naing disclose research funding from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, Surface Oncology, Monopteros Therapeutics, BioNTech SE, Seven & Eight Biopharma, and SOTIO Biotech AG. Advisory board activity for CytomX Therapeutics, Novartis, Genome & Company, OncoSec KEYNOTE-695, Kymab, STCube Pharmaceuticals, and Deka Biosciences. He reports advisory board role for Takeda, CSL, Behring, Horizon, and Pharming. Travel and accommodation expense from ARMO BioSciences: Spouse and research funding from Immune Deficiency Foundation, Jeffery Modell Foundation and chao physician-scientist, and Baxalta. F. R. Hirsch reports advisory boards consultancy for Bristol-Myers Squibb, AstraZeneca/Daiichi, Sanofi/Regeneron, Novartis, Amgen, OncoCyte, Genentech, and Nectin Therapeutics. C. Rolfo is a speaker for Merck Sharp and Dohme, AstraZeneca, COR2ED, Guardant Health, and Roche (CH); has research collaborations (non-financial support) with Guardant Health; advisory board activity: Archer, Inivata, Boston pharmaceutical, EMD Serono, Novartis, Pfizer, Mirati, Eisai, Daiichi Sankyo, Sanofi Genzyme-Regeneron, and BMS. Research grant from LCRF-Pfizer. The rest of the authors declares no competing interest.